The receptor activator of nuclear factor-kB inhibitor osteoprotegerin is a bone-protective agent in a rat model of chronic renal insufficiency and hyperparathyroidism. Padagas J, Colloton M, Shalhoub V, Kostenuik PJ, et al. Calcif Tissue Intl 78: 35-44, 2006. PMID: 16362459

 RANKL inhibition by OPG prevents focal bone erosions in arthritic rats without inducing renal pathology: Comparison with zoledronic acid. Stolina M, Ominsky MS, Middleton S, Adamu S, Dywer D, Asuncion F, Geng Z, Zack D, McDormand D, Kostenuik PJ.  Arthritis and Rheumatism 20 (Suppl) S157, 2005 (Abstract).

Osteoprotegerin is a bone protective agent in a rat model of chronic renal insufficiency and hyperparathyroidism. Shalhoub V, Padagas J, Colloton M, Shatzen E, Morony S, Kostenuik PJ, Dunstan CR, Lacey DL, et al. J Bone Miner Res 19 (Suppl. 1): S331, 2004 (Abstract).

Some of Dr. Kostenuik's publications in the renal field

Drawing on an understanding of the bone-kidney axis, which includes important co-regulation of mineral homeostasis, Paul spent several recent years  seeking novel targets and therapeutic strategies to manage kidney diseases, including CKD-MBD, PKD, hyperphosphatemia, and secondary hyperparathyroidism.  He also studied kidney pathology  and toxicity as it relates to large and small molecule therapeutics. A personal highlight was a recent return to his alma mater, McMaster University, to deliver a Kidney Grand Rounds lecture. 

Renal